In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast cancer than does conventional IHC-FISH pathology testing.

Makers of F-18 florbetapir (Amyvid) are bankrolling a lawsuit against the Centers for Medicare & Medicaid Services (CMS), which hampered coverage of amyloid imaging earlier this year as a means for ruling out Alzheimer’s disease. The lawsuit was filed in federal court by Lilly and others Sept. 5, according to this Wall Street Journal report.

The Centers for Medicare & Medicaid Services (CMS) has provided projected U.S. healthcare spending for the next several years and it is modest. Due to a timid economy and higher private insurance plan costs that pinch demand for healthcare services, average annual healthcare spending is expected to grow by 5.7 percent this year and just about 6 percent from 2013 to 2023.

In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional IHC-FISH pathology tests.

In the world of cancer screening, there may be a bias of accessibility that is skewed toward more screening when doctors are paid more by Medicaid, according to a study conducted by the division of health services and social policy research at RTI International in Washington, D.C.

Researchers from the University of California, Davis, have created dynamic nanoparticles that can be used to both diagnose and treat cancer.

Radiant Sage LLC, a provider of on-demand clinical trial imaging infrastructure solutions, today announced that it has been named to CIOReview's list of 100 Most Promising Technology Companies. The CIOReview100 includes companies that are gaining momentum in the technology industry and making an impact.

Chronic pain is associated with a reduction in reward seeking, but not just because people are hurting and do not feel up to the task. New Stanford brain research is providing a more comprehensive picture of how molecular changes in the brain dictate loss of motivation in painful settings.